Short-acting benzodiazepine Pregnancy: Benzodiazepines should not be used during pregnancy, especially during the first and last trimesters, and may cause foetal damage. Women of childbearing potential should be warned to contact their physician regarding discontinuance if they intend to become or suspect they are pregnant. Infants born to mothers who took benzodiazepines chronically in later pregnancy may develop physical dependence and postnatal withdrawal symptoms (hypoactivity, hypotonia, hypothermia, respiratory depression, apnoea, feeding problems, impaired metabolic response to cold stress). The concentration of oxazepam and its conjugate in human breast milk is approximately 10% of the plasma level — oxazepam should not be administered to breast-feeding mothers.

Oxazepam

Oxazepam is a short- to intermediate-acting benzodiazepine used for the short-term relief of anxiety and associated insomnia.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Anxiety: 15–30 mg. Insomnia associated with anxiety: generally 15–25 mg, increased to a maximum of 50 mg when necessary

Route: Oral

Frequency: Anxiety: three or four times daily. Insomnia associated with anxiety: one hour before retiring

Max: 50 mg per dose for insomnia associated with anxiety ('This may be increased to a maximum of 50mg when necessary'). No overall maximum daily dose is stated in §4.2 for the anxiety regimen.

SPC §4.2 (Oxazepam 10mg Tablets): 'Adults: Anxiety 15-30mg three or four times daily. Insomnia associated with anxiety: Generally 15-25mg one hour before retiring. This may be increased to a maximum of 50mg when necessary.' Before starting, a strategy for ending treatment should be agreed with the patient to minimise the risk of dependence, addiction and withdrawal syndrome. Treatment should be given for the shortest possible duration; dosage and duration should be individualised and all patients carefully monitored and re-evaluated before any extension. Long-term chronic use is not recommended. As an anxiolytic, the lowest effective dose should be employed for the shortest time possible; dosage regimens 'should not exceed beyond 4 weeks, including the period of tapering off', and treatment should always be withdrawn gradually. ELDERLY and those particularly sensitive to benzodiazepines: 10–20 mg three or four times a day. RENAL/HEPATIC: 'in patients with renal or hepatic impairment, lower doses may be sufficient'. PAEDIATRIC: 'Not recommended for children' — no paediatric dose is given in this source. CROSS-CHECK: the US label (American Health Packaging, 2024-11-14) gives mild-to-moderate anxiety 10–15 mg 3 or 4 times daily; severe anxiety syndromes, agitation, or anxiety associated with depression 15–30 mg 3 or 4 times daily; alcoholics with acute inebriation, tremulousness or anxiety on withdrawal 15–30 mg 3 or 4 times daily; older patients initial 10 mg 3 times daily, increased cautiously to 15 mg 3 or 4 times daily if necessary. The US label states it is not indicated in patients under 6 years of age and that absolute dosage for those aged 6 to 12 years is not established.

Dose adjustments

Renal

No specific dose stated. §4.2: 'in patients with renal or hepatic impairment, lower doses may be sufficient' (see §4.4).

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to benzodiazepines or to any of the excipients
Phobic or obsessional states
Treatment of chronic psychosis
Acute pulmonary insufficiency
Respiratory depression
Myasthenia gravis
Sleep apnoea syndrome
Severe hepatic insufficiency

Side effects

Mild drowsiness (commonly seen in the first few days of therapy — reduce dosage if troublesome), lethargy, reduced alertness
Dizziness, light-headedness, ataxia, vertigo, headache, slurred speech, tremor
Blurred vision, double vision
Hypotension; falls
Muscle weakness
Amnesia, disorientation, confusion; paradoxical reactions (aggressive outbursts, excitement, hallucinations, agitation, irritability) — more likely in children and the elderly
Drug dependence and withdrawal symptoms on discontinuation

Interactions

Alcohol and other CNS depressants — tolerance for these is diminished in the presence of oxazepam; they should either be avoided or taken in reduced dosage (§4.4; §4.5 was not included in the fetched bundle)
Drugs that lower the convulsive threshold, such as antidepressants — convulsions during withdrawal may be more common in patients taking these or with pre-existing seizure disorders (§4.8)

Clinical monograph

How it works

It enhances the inhibitory action of GABA at the GABA-A receptor, increasing chloride conductance to produce anxiolytic, sedative and hypnotic effects.

Prescribing in practice

Benzodiazepines should be used at the lowest effective dose for the shortest possible period because of the risk of tolerance, dependence and a withdrawal syndrome.
There is additive sedation and respiratory depression with alcohol, opioids and other CNS depressants.
Because it does not require oxidative hepatic metabolism, oxazepam is sometimes preferred in hepatic impairment and in the elderly, but caution and reduced exposure are still warranted.

Monitoring

Review the ongoing need for treatment regularly and monitor for excessive sedation, falls and emerging dependence.

Counselling the patient

This medicine can cause drowsiness; avoid driving or operating machinery if affected.
Do not drink alcohol while taking oxazepam.
Do not stop suddenly after regular use; your prescriber will arrange a gradual reduction.

Evidence & guidelines

NICE and MHRA guidance support short-term, lowest-effective use of benzodiazepines such as oxazepam for anxiety because of the risk of dependence.

Reference: NICE TA77; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways